Skip to main content
SpringerLink
Log in

Bortezomib/dexamethasone/lenalidomide

Neuropathy and cytopenia: 2 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Hussaini S, et al. Weekly dosing of bortezomib in rvd achieves minimal toxicity with no reduction in efficacy in a diverse cohort of multiple myeloma patients. Blood 130 (Suppl. 1): 5425, Dec 2017 [abstract] - USA

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bortezomib/dexamethasone/lenalidomide. Reactions Weekly 1695, 77 (2018). https://doi.org/10.1007/s40278-018-43904-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-43904-2

Search

Navigation